Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.

Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, Zulu I, Kankasa C, Wilfert C, Weidle PJ, Vermund SH, Stringer JS.

AIDS. 2007 May 11;21(8):957-64.

2.

Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.

Chintu N, Giganti MJ, Putta NB, Sinkala M, Sadoki E, Stringer EM, Stringer JS, Chi BH.

Trop Med Int Health. 2010 Jul;15(7):842-7. doi: 10.1111/j.1365-3156.2010.02540.x. Epub 2010 May 7.

3.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
4.

Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(5):CD004772.

PMID:
22786492
5.

Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.

Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, Jariyasethpong T, Potter D, Mutsotso W, Borkowf CB, Mbori-Ngacha D, Muiruri P, Ong'ech JO, Zulu I, Njobvu L, Jetsawang B, Pathak S, Bulterys M, Shaffer N, Weidle PJ.

PLoS Med. 2010 Feb 16;7(2):e1000233. doi: 10.1371/journal.pmed.1000233.

6.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
7.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
8.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
9.

Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.

Mudiope PK, Kim S, Wabwire D, Nyende L, Bagenda D, Mubiru M, Mulira R, Elbireer S, Namukwaya Z, Fowler MG, Musoke P.

Trop Med Int Health. 2013 Mar;18(3):344-51. doi: 10.1111/tmi.12054. Epub 2013 Jan 4.

10.

Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.

Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL; International PACTG 316 Team.

JAMA. 2002 Jul 10;288(2):189-98.

PMID:
12095383
11.

A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.

Samuel R, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.

J Med Virol. 2015 Oct;87(10):1662-7. doi: 10.1002/jmv.24220. Epub 2015 May 4.

12.

Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.

Kuhn L, Semrau K, Ramachandran S, Sinkala M, Scott N, Kasonde P, Mwiya M, Kankasa C, Decker D, Thea DM, Aldrovandi GM.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):132-6. doi: 10.1097/QAI.0b013e3181ab6d5e.

13.

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.

Clin Infect Dis. 2008 Mar 15;46(6):933-40. doi: 10.1086/528861.

PMID:
18271750
14.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
15.

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.

Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F; Ghent Group on HIV in Women and Children.

Int J Epidemiol. 2007 Oct;36(5):1009-21. Epub 2007 May 28. Review.

PMID:
17533166
16.

Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.

Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):350-64.

PMID:
11468423
17.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

18.

Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.

Stringer JS, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, Kumwenda-Phiri R, Vermund SH.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):506-13.

19.

Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.

Ngemu EK, Khayeka-Wandabwa C, Kweka EJ, Choge JK, Anino E, Oyoo-Okoth E.

BMC Res Notes. 2014 Jan 21;7:52. doi: 10.1186/1756-0500-7-52. Retraction in: BMC Res Notes. 2014;7:868.

20.

Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.

Mwesigire DM, Wu AW, Martin F, Katamba A, Seeley J.

BMC Health Serv Res. 2015 Jul 28;15:292. doi: 10.1186/s12913-015-0959-0.

Supplemental Content

Support Center